Kiniksa Pharmaceuticals International plc Aktie News & Nachrichten

[WKN: A2JMVJ | Symbol: KNSA]
Realtimekurs
   
Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, Vixarelimab, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Lexington, MA.

Kiniksa Pharmaceuticals Ltd. (KNSA): Citigroup sieht 78 % Kurspotenzial und nennt Kriterien für präferierte Biotechs!

Kiniksa Pharmaceuticals Ltd. (KNSA) ist ein Biotechnologieunternehmen, welches sich auf schwerwiegende...

  • ‹
  • 1
  • ›